Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
Open Access
- 20 May 2015
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 137 (10), 2513-2519
- https://doi.org/10.1002/ijc.29612
Abstract
Acquired estrogen receptor gene (ESR1) mutations have been recently reported as a marker of resistance to aromatase inhibitors in hormone receptor positive metastatic breast cancer. We retrospectively considered seven patients treated for metastatic breast cancer with available samples from the primary tumor before any treatment, cryopreserved metastasis removed during progression and concomitant plasmas. All these seven patients were in disease progression after previous exposure to aromatase inhibitors for at least 6 months, and were assessed for ESR1 mutations detection in tumor and circulating DNA. For these patients, Sanger sequencing identified four metastases with clear ESR1 mutation and one possible, whereas digital PCR identified six mutated metastases. Then, under blind conditions and using digital PCR, corresponding circulating ESR1 mutations were successfully detected in four of these six metastatic breast cancer patients. Moreover, in two patients with serial blood samples following treatments exposure, the monitoring of circulating ESR1 mutations clearly predicted disease evolution. In the context of high interest for ESR1 mutations, our results highlight that these acquired recurrent mutations may be tracked in circulating tumor DNA and may be of clinical relevance for metastatic breast cancer patient monitoring.Keywords
Funding Information
- INSERM U1079 and the Centre Henri Becquerel
This publication has 22 references indexed in Scilit:
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)Annals Of Oncology, 2014
- Estrogen Receptor Mutations in Breast Cancer—New Focus on an Old TargetClinical Cancer Research, 2014
- Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2014
- D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast CancerCancer Research, 2013
- The search for ESR1 mutations in breast cancerNature Genetics, 2013
- Activating ESR1 mutations in hormone-resistant metastatic breast cancerNature Genetics, 2013
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancerNature Genetics, 2013
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsCell Reports, 2013
- UK Guidance Document: Treatment of Metastatic Breast CancerClinical Oncology, 2012
- Aromatase Inhibitor Versus Tamoxifen in Postmenopausal Woman With Advanced Breast Cancer: A Literature-Based Meta-AnalysisClinical Breast Cancer, 2011